Anno I | Numero 6 | Ottobre 2016
Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio
Editore: Intermedia – Direttore Responsabile: Mauro Boldrini
Notizie dalla ricerca
Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management
Immune checkpoint inhibitors such as those that target the programmed cell death (PD)-1 pathway harness the host immune system to elicit an antitumor response. Their remarkable clinical benefit has led to regulatory approvals in several malignancies including the genitourinary cancers, renal cell carcinoma, and urothelial carcinoma. This review will focus on the management of the toxicities encountered with these agents. Although generally well tolerated, a small proportion of patients …
Continua a leggere
The prospect of precision therapy for renal cell carcinoma
The therapeutic landscape of renal cell carcinoma (RCC) has greatly expanded in the last decade. From being a malignancy orphan of effective therapies, kidney cancer has become today a tumor with several treatment options. Renal cell carcinoma (RCC) is a metabolic disease, being characterized by the dysregulation of metabolic pathways involved in oxygen sensing (VHL/HIF pathway alterations and the subsequent up-regulation of HIF-responsive genes such as VEGF, PDGF, EGF, and glucose …
Continua a leggere
Immunobiology and immunotherapy in genitourinary malignancies
Immunotherapy has traditionally been a critical component of the cancer treatment armamentarium in genitourinary (GU) cancers. It has an established role in the management of carefully selected patients with metastatic renal cell carcinoma (RCC) [e.g., high dose interleukin-2 (IL-2)] and non-muscle invasive bladder cancer (NMIBC) [e.g., intravesical Bacillus Calmette-Guérin (BCG)]. In 2010, the sipuleucel-T vaccine was approved by the FDA for the management of metastatic castration-resistant …
Continua a leggere
The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma
Pretreatment tumor PD-L1 expression has been shown to correlate with response to anti-PD-1/PD-L1 therapies. Yet, most patients with PD-L1+ tumors do not respond to treatment. The current study was undertaken to investigate mechanisms underlying the failure of PD-1-targeted therapies in patients with advanced renal cell carcinoma (RCC) whose tumors express PD-L1. Formalin-fixed, paraffin-embedded pretreatment tumor biopsies expressing PD-L1 were derived from 13 RCC …
Continua a leggere
PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Immune checkpoint inhibitors targeting the inhibitory cross talk between tumor and immune cells have been approved for therapy in renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known on PD-1/PD-L1 expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of PD-1 and PD-L1 expression in chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimen was …
Continua a leggere
Appuntamenti AIOM
XVIII Congresso Nazionale AIOM
Roma, 28 – 30 ottobre 2016
Link all'evento
Hot Topics in Oncologia 2016
Fiuggi (FR), 22 ottobre 2016
Dialoghi sull'Immunoterapia dei Tumori dell'AIOM Campania
Salerno, 25 ottobre 2016
Dialoghi sull'Immunoterapia dei Tumori dell'AIOM Campania
Avellino, 3 novembre 2016
4th International Conference 'Translational Research in Oncology'
Meldola (FC), 8 novembre 2016
Forlì, 9 – 11 novembre 2016
Immuno-Oncologia: Stato dell'Arte e Update
Cagliari, 9 novembre 2016
IV Meeting Uro-Oncologico: Update 2016 sui tumori urologici
Fano (PU), 11 – 12 novembre 2016
Nuove Frontiere Diagnostico-Terapeutiche nelle Neoplasie Polmonari, Renali e nel Melanoma
Varese, 12 novembre 2016
5th World Top Communications of the Year in Genito-Urinary Oncology
Arezzo, 17 – 18 novembre 2016
Conferenza Annuale SIOG 2016
Geriatric Oncology: a multidisciplinary approach in a global environment
Milano, 17 – 19 novembre 2016
Coniugare Innovazione, Sostenibilità e Continuità di Cura in Oncologia
Il Ruolo delle Reti Regionali
Milano, 19 novembre 2016
First International Congress
Clinical Needs and Translational Research in Oncology
Reggio Emilia, 28 – 29 novembre 2016
Immunotherapy Bridge 2016
Napoli, 30 novembre 2016
Questi e altri appuntamenti si possono consultare sul sito AIOM

Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Per contattare la redazione e commentare le notizie clicca qui: redazione
Per consultare i numeri arretrati della newsletter clicca qui: archivio
Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI

Questo progetto è stato realizzato con il contributo di